Public Policy Resources

To ensure that the research being conducted today yields the cancer treatments of tomorrow, Congress must sustain and expand the support it is currently providing. ACS CAN urges Congress to provide $51.3 billion for NIH and $7.93 billion for NCI for FY2026. 

In response to a Department of Commerce request, ACS CAN submitted comments on the role of pharmaceutical products manufactured outside of the U.S. and the potential impacts that tariffs could have on the availability of generic sterile injectable drugs needed by patients with cancer. 

The Congressionally Directed Medical Research Program (CDMRP) has been funding cancer research for over 30 years and is a significant source of grants.  The recent continuing resolution to fund the FY25 budget cut the CDMRP program significantly. 

As policymakers consider changes to the 340B program, there is increasing interest in whether and how the drug discounts potentially affect the delivery of cancer care. Just as oncology influences the 340B program’s scope and growth, this study found that the 340B program influences the delivery of cancer care in the US. 

LUNGevity and ACS CAN partnered with Bruce Quinn Associates to develop materials to engage hospitals on pathologist-initiated biomarker testing, providing an overview of the MolDx clarification on CMS "treating physician" guidance.

ACS CAN is joined by 21 partner advocacy and professional society partners in requesting a safe harbor from the Anti-Kickback Statute (AKS) for financial support of clinical trial participants.

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice.

A coalition of 74 patient and provider groups has offered their support of H.R. 8412, the Clinical Trial Modernization Act, which would remove tax liabilities for financial support received while on clinical trials as well as create a safe harbor for sponsors offering such support.  

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.